

# Alessandro Ferrari

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8328894/publications.pdf>

Version: 2024-02-01

28  
papers

1,378  
citations

566801

15  
h-index

525886

27  
g-index

32  
all docs

32  
docs citations

32  
times ranked

3712  
citing authors

#	ARTICLE	IF	CITATIONS
1	Performance of VivaDiag COVID-19 IgM/IgG Rapid Test is inadequate for diagnosis of COVID-19 in acute patients referring to emergency room department. <i>Journal of Medical Virology</i> , 2020, 92, 1724-1727.	2.5	205
2	Tocilizumab for Treatment of Severe COVID-19 Patients: Preliminary Results from SMAtteo COVID19 REgistry (SMACORE). <i>Microorganisms</i> , 2020, 8, 695.	1.6	186
3	Prevalence of SARS-CoV-2 specific neutralising antibodies in blood donors from the Lodi Red Zone in Lombardy, Italy, as at 06 April 2020. <i>Eurosurveillance</i> , 2020, 25, .	3.9	158
4	Severe acute respiratory syndrome coronavirus 2 RNA contamination of inanimate surfaces and virus viability in a health care emergency unit. <i>Clinical Microbiology and Infection</i> , 2020, 26, 1094.e1-1094.e5.	2.8	121
5	Clinical characteristics of coronavirus disease (COVID-19) early findings from a teaching hospital in Pavia, North Italy, 21 to 28 February 2020. <i>Eurosurveillance</i> , 2020, 25, .	3.9	119
6	SARS Cov-2 infection in a renal-transplanted patient: A case report. <i>American Journal of Transplantation</i> , 2020, 20, 1882-1884.	2.6	76
7	EBV DNA increase in COVID-19 patients with impaired lymphocyte subpopulation count. <i>International Journal of Infectious Diseases</i> , 2021, 104, 315-319.	1.5	66
8	Immunity to SARS-CoV-2 up to 15 months after infection. <i>IScience</i> , 2022, 25, 103743.	1.9	56
9	SARS-CoV-2 vaccine breakthrough infections with the alpha variant are asymptomatic or mildly symptomatic among health care workers. <i>Nature Communications</i> , 2021, 12, 6032.	5.8	55
10	Lack of SARS-CoV-2 RNA environmental contamination in a tertiary referral hospital for infectious diseases in Northern Italy. <i>Journal of Hospital Infection</i> , 2020, 105, 474-476.	1.4	51
11	Emergency Department and Out-of-Hospital Emergency System (112-AREU 118) integrated response to Coronavirus Disease 2019 in a Northern Italy centre. <i>Internal and Emergency Medicine</i> , 2020, 15, 825-833.	1.0	50
12	SARS-CoV-2 specific T-cell immunity in COVID-19 convalescent patients and unexposed controls measured by ex vivo ELISpot assay. <i>Clinical Microbiology and Infection</i> , 2021, 27, 1029-1034.	2.8	49
13	Rapid response to COVID-19 outbreak in Northern Italy: how to convert a classic infectious disease ward into a COVID-19 response centre. <i>Journal of Hospital Infection</i> , 2020, 105, 477-479.	1.4	31
14	Humoral and cell-mediated response against SARS-CoV-2 variants elicited by mRNA vaccine BNT162b2 in healthcare workers: a longitudinal observational study. <i>Clinical Microbiology and Infection</i> , 2022, 28, 301.e1-301.e8.	2.8	28
15	Residual SARS-CoV-2 RNA in nasal swabs of convalescent COVID-19 patients: Is prolonged quarantine always justified?. <i>International Journal of Infectious Diseases</i> , 2021, 102, 299-302.	1.5	27
16	Macrophages and Monocytes: "Trojan Horses" in COVID-19. <i>Viruses</i> , 2021, 13, 2178.	1.5	18
17	Robust and Persistent B- and T-Cell Responses after COVID-19 in Immunocompetent and Solid Organ Transplant Recipient Patients. <i>Viruses</i> , 2021, 13, 2261.	1.5	10
18	Seroprevalence of SARS-CoV-2 in blood donors from the Lodi Red Zone and adjacent Lodi metropolitan and suburban area. <i>Clinical Microbiology and Infection</i> , 2021, 27, 914.e1-914.e4.	2.8	9

#	ARTICLE	IF	CITATIONS
19	Immune Response to BNT162b2 in Solid Organ Transplant Recipients: Negative Impact of Mycophenolate and High Responsiveness of SARS-CoV-2 Recovered Subjects against Delta Variant. <i>Microorganisms</i> , 2021, 9, 2622.	1.6	9
20	Venous thromboembolism and COVID-19: a single center experience from an academic tertiary referral hospital of Northern Italy. <i>Internal and Emergency Medicine</i> , 2021, 16, 1141-1152.	1.0	8
21	Characterization of Varicella-Zoster (VZV) Specific T Cell Response in Healthy Subjects and Transplanted Patients by Using Enzyme Linked Immunospot (ELISpot) Assays. <i>Vaccines</i> , 2021, 9, 875.	2.1	7
22	Variant of Concern-Matched COVID-19 Convalescent Plasma Usage in Seronegative Hospitalized Patients. <i>Viruses</i> , 2022, 14, 1443.	1.5	7
23	<scp>Neutralizing antibody levels against SARSâ€CoV</scp> â€2 <scp>variants of concern Delta and Omicron in vaccine breakthroughâ€infected blood donors</scp>. <i>Transfusion</i> , 2022, , .	0.8	5
24	Low risk for SARS-CoV2 symptomatic infection and early complications in paediatric patients during the ongoing CoVID19 epidemics in Lombardy. <i>Clinical Microbiology and Infection</i> , 2020, 26, 1569-1571.	2.8	4
25	Detection of the SARSâ€CoVâ€2 in different biologic specimens from positive patients with COVIDâ€19, in Northern Italy. <i>Pediatric Allergy and Immunology</i> , 2020, 31, 72-74.	1.1	4
26	SARS-CoV-2 variants inactivation of plasma units using a riboflavin and ultraviolet light-based photochemical treatment. <i>Transfusion and Apheresis Science</i> , 2022, 61, 103398.	0.5	4
27	Impact of pathogen reduction technology on neutralizing antibody titer in COVID-19 convalescent plasma. <i>Transfusion Clinique Et Biologique</i> , 2021, 29, 101-101.	0.2	1
28	Impact of Viral Decontamination Method on Cytokine Profile of COVID-19 Patients. <i>Biomedicines</i> , 2021, 9, 1287.	1.4	0